Showing results (231-240 of 252) with videos related to

Sort By:
Pageof 26
Cardiovascular Research|September 22, 2021
The adult heart requires baseline expression of the transcription factor Hand2 to withstand right ventricular pressure overloadRaquel F Videira, Anne Marie C Koop, Lara Ottaviani, et al.
Metabolomics : Official Journal of the Metabolomic Society|July 1, 2016
Recon 2.2: from reconstruction to model of human metabolismNeil Swainston, Kieran Smallbone, Hooman Hefzi, et al.
The Journal of Dermatological Treatment|January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohortDiego Orsini, Luca Potestio, Matteo Megna, et al.
Biology|June 27, 2024
Genetic and Phenotypic Evaluation of European Maize Landraces as a Tool for Conservation and Valorization of AgrobiodiversityCarlotta Balconi, Agustin Galaretto, Rosa Ana Malvar, et al.
Nature Biotechnology|December 8, 2004
A proposed framework for the description of plant metabolomics experiments and their resultsHelen Jenkins, Nigel Hardy, Manfred Beckmann, et al.
FEBS Letters|July 9, 2013
A model of yeast glycolysis based on a consistent kinetic characterisation of all its enzymesKieran Smallbone, Hanan L Messiha, Kathleen M Carroll, et al.
American Journal of Clinical Dermatology|March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|September 10, 2025
Deep Vein Thrombosis in Critically Ill Patients With COVID-19 Pneumonia: Incidence, Wells Score Diagnostic Performance, and Hospital PrognosisClévio Cezar da Fonseca, Hugo Perazzo, Sandra Wagner Cardoso, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Lancet (London, England)|February 6, 2023
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trialsAlexa B Kimball, Gregor B E Jemec, Afsaneh Alavi, et al.
Pageof 26